Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough Cancer Pain With Freedom From Oral Discomfort Through the Use of Abstral® (Fentanyl) Sublingual Tablets

NCT01936636 is registered in ClinicalTrials.gov with Galena Biopharma, Inc. as lead sponsor.

NCT NCT01936636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01936636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough Cancer Pain With Freedom From Oral Discomfort Through the Use of Abstral® (Fentanyl) Sublingual Tablets
Lead sponsor
Galena Biopharma, Inc.
Phase
Observational
Overall status
Completed
Start date
October 31, 2013
Completion date
June 30, 2015
Enrollment
164 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

breakthrough cancer pain, quality of life